Table 2 Primary and secondary outcomes according to the study groups: dobutamine-sparing (80 patients) and dobutamine-to-all (80 patients)
Variable | Dobutamine-sparing | Dobutamine-to-all | Absolute difference | p-value |
|---|---|---|---|---|
n = 80 | n = 80 | (95% CI) | ||
Primary composite endpoint | 25 (31%) | 27 (34%) | 2.5 (− 11.8 to 16.7) | 0.74b |
Arrhythmias (supraventricular and/or ventricular), n (%) | 19 (24%) | 22 (28%) | 3.7 (− 9.7 to 17.1) | 0.59b |
Low cardiac output syndromee, n (%) | 11 (14%) | 12 (15%) | 1.2 (− 9.9 to 12.4) | 0.82b |
Cardiogenic shock, n (%) | 9 (11%) | 11 (14%) | 2.5 (− 8.1 to 13.1) | 0.63b |
Death, n (%) | 2 (2.5%) | 5 (6.3%) | 3.8 (− 3.4 to 11.5) | 0.44d |
Acute myocardial infarction, n (%) | 1 (1.3%) | 2 (2.5%) | 1.2 (− 4.5 to 7.5) | 0.99d |
Stroke, n (%) | 2 (2.5%) | 0 | − 2.5 (− 8.7 to 2.4) | 0.50d |
Secondary outcomes | ||||
Atrial fibrillation, n (%) | 19 (24%) | 20 (25%) | 1.2 (− 12.0 to 14.4) | 0.85b |
Heart failure, n (%) | 11 (14%) | 11 (14%) | 0 (− 10.9 to 10.9) | 0.99b |
Acute kidney failure (AKIN Stage ≥ 2), n (%) | 10 (13%) | 11 (14%) | 1.3 (− 9.5 to 12.0) | 0.82b |
Renal replacement therapy, n (%) | 7 (8.8%) | 3 (3.8%) | − 5.0 (− 13.6 to 3.1) | 0.19b |
Septic shock, n (%) | 3 (3.8%) | 1 (1.3%) | − 2.5 (− 9.3 to 3.5) | 0.62d |
Mechanical ventilation > 48 h, n (%) | 3 (3.8%) | 4 (5.0%) | 1.3 (− 6.1 to 8.8) | 0.99d |
Red blood cell transfusion, n (%) | 10 (13%) | 9 (11%) | − 1.2 (− 11.7 to 9.1) | 0.81b |
SOFA (72 h), median (IQR) | 3 (2–6) | 3 (1–5) | – | 0.29a |
Highest lactate (mmol/L), median (IQR) | 3.9 (2.8–5.1) | 4.0 (3.0–6.4) | 0.47a | |
Length of ICU stay (days), median (IQR) | 3 (2–5) | 3 (2–4) | – | 0.27a |
Length of hospital stay (days), median (IQR) | 14 (11–19) | 13 (9–17) | – | 0.25a |
ICU readmission, n (%) | 2 (2.6%) | 1 (1.3%) | − 1.3 (− 7.5 to 4.5) | 0.99d |